NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
Boston, MA
